Hemab Therapeutics Appointed Keli Walbert to Board
The biopharmaceutical company added Keli Walbert to its board of directors and its audit committee.
Updated on Sept. 24, 2026 in People
Live Poll
Do you trust that changing corporate board leadership improves the development of new life-saving medical therapies?
Hemab Therapeutics has appointed Keli Walbert to its board of directors. Walbert also joins the board's audit committee, succeeding Akshay Vaishnaw in that role.
Why it matters
The company added Walbert to its leadership team to leverage her extensive commercial experience as it works to advance its pipeline toward later-stage development.
Keli Walbert brings more than 20 years of commercial leadership experience in biopharmaceuticals to the board. During her time at Horizon Therapeutics, she previously oversaw a portfolio of 10 marketed brands.
The players
Keli Walbert
She is a veteran biopharmaceutical executive who previously served as an Executive Vice President at Horizon Therapeutics.
Akshay Vaishnaw
He is a current board member at Hemab Therapeutics who previously served on the company's audit committee.
Hemab Therapeutics
The company is a clinical-stage biotechnology firm with offices located in Cambridge and Copenhagen.
The details
Walbert joins the Cambridge-based firm following a career that included executive leadership roles at Horizon Therapeutics, AbbVie, and Abbott. Akshay Vaishnaw will continue his tenure as a member of the company's board of directors.
Timeline
Keli Walbert officially joined the board of directors on September 24, 2026.
Market Landscape
The move reflects a wider trend among clinical-stage biotech companies shifting focus toward long-term commercialization strategies. By securing veteran leadership, Hemab Therapeutics aims to strengthen its competitive position against rivals as its pipeline matures.
For stakeholders and investors, this board shift signals a push toward commercial viability for the firm's drug pipeline. Customers and partners can expect the company to place a higher priority on market-ready operations under the new leadership structure.
The takeaway
Adding executives with deep experience in commercializing pharmaceutical products is a common strategy for growth-stage biotech firms. This move suggests that Hemab Therapeutics is preparing for a significant evolution in its operational goals.
Further reading
Learn more about the latest leadership changes in the industry by visiting the People section.
Live Poll
Do you trust that changing corporate board leadership improves the development of new life-saving medical therapies?
